European Commission Approves Dupilumab for Severe Asthma |
Molecule Updates
eMediNexus Coverage from: 
European Commission Approves Dupilumab for Severe Asthma

0 Read Comments                

The European Commission (EC) has approved dupilumab (Dupixent) as add-on maintenance therapy for patients 12 years or older with severe asthma with type 2 inflammation characterized by increased blood eosinophil levels and/or increased fractional exhaled nitric oxide, whose condition is poorly controlled with high-dose inhaled corticosteroid plus another medicine.

The move follows a recommendation for approval by the European Medicines Agencys Committee for Medicinal Products for Human Use back in March.

The drug is already approved in Europe for treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now